Literature DB >> 22332967

Stage of chronic kidney disease and severity of coronary heart disease manifestation.

Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P Mikhailidis.   

Abstract

A recent study suggested that patients with chronic kidney disease (CKD) with a glomerular filtration rate (GFR) < 45 ml/min/1.73 m(2) are more likely to present with acute myocardial infarction (AMI) than with stable exertion angina. Thus, the degree of renal impairment seems to be related to the presentation of coronary heart disease (CHD). In this context, there is evidence indicating that statins decrease the excess risk for AMI and other CHD-related events in patients with CKD (although the benefit may depend on the stage of CKD). This effect might be attributed to stabilization of atherosclerotic plaques, which seem to be more vulnerable if CKD is present. Thus, statin treatment in early CKD, a condition considered to be a CHD equivalent by several guidelines, is likely to minimize the risk for CHD events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22332967     DOI: 10.1517/14656566.2012.661716

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  Leptin, cardiovascular diseases and type 2 diabetes mellitus.

Authors:  Niki Katsiki; Dimitri P Mikhailidis; Maciej Banach
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

2.  Bidirectional and Temporal Association Between Hypertension and Microalbuminuria: A Longitudinal Study in Chinese Adults.

Authors:  Mingzhi Zhang; Yanbo Jiang; Qiu Zhang; Yan Chen; Yan He; Yao Lin; Hao Peng
Journal:  J Am Heart Assoc       Date:  2018-11-20       Impact factor: 5.501

3.  Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters.

Authors:  Vasilios G Athyros; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2012-09-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.